The GAO report highlights FDA's drug inspection program challenges, including 36% fewer inspections in 2023 compared to 2019 ...
The amylin field is heating up ahead of Novo Nordisk's much-anticipated CagriSema readout later this year. On Wednesday, ...
Adaptimmune announced Wednesday that its experimental cell therapy based on T cell receptors shrank tumors by at least 30% in ...
Forward Health, a San Francisco-based primary care startup offering $150 monthly subscription services through ...
Johnson & Johnson is suing the federal government over its rebuke of the company’s alternative model for 340B ...
TRexBio secured $84 million Series B funding, led by Delos Capital with Eli Lilly and Johnson & Johnson participating, to ...
A lot of Amgen's future rides on its experimental obesity medicine MariTide. At least in the minds of investors. Ahead of the ...
BioNTech is acquiring Chinese biotech Biotheus for $800 million upfront plus $150 million in milestones, gaining multiple ...
Otsuka Pharmaceutical Factory and ICU Medical have formed a $200 million joint venture to bolster the US IV product supply ...
Just seven months after unveiling with $290 million, obesity biotech Metsera is back with another $215 million.
Flagship Pioneering has appointed two new CEO-partners to advise its portfolio companies and help steer its ...
Pfizer, reportedly working with Goldman Sachs, is considering selling its hospital drugs unit while facing pressure from ...